LUMEN
9.3.2021 14:22:05 CET | Business Wire | Press release
Lumen , the creators of the world's first metabolism measurement device through the breath, have teamed up with the UK's top personal trainer, Harry Jameson, to raise awareness on metabolic health for March Metabolism Awareness Month .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210309005629/en/
Harry is available for expert commentary on training to improve your metabolism.
"Having the ability to move between energy sources (fat and carbohydrates) is extremely important. It is a measure of your metabolic health and I’ve been working hard over the past two months to improve mine.
Using Lumen to track whether my diet, fasting or even training is pushing my metabolism in the right direction has been both fascinating from a coaches perspective and incredibly insightful from a user/customer perspective. I love how lumen keeps me both accountable and consistent with my behaviours and getting personalised nutrition plans really helps take a mental load off my shoulders in my busy schedule," says personal trainer Jameson.
Lumen and Jameson are also working together to emphasise the importance of metabolic health in combating metabolic syndrome. In the UK, 1 in 3 adults over the age of 50 will suffer from metabolic disease which is a combination of diabetes, high blood pressure (hypertension) and obesity.
The power to move away from metabolic disease by training your metabolism to switch efficiently between carbs and fats as a fuel source is a term called metabolic flexibility .
"If we feed and train our metabolism, we can process our food more efficiently - you may be able to eat a slice of pie and use it for energy faster if you have a good metabolism. We are merely training our body to use fuel sources properly- an innate mechanism. There's really no need to crash diet , if we take care of our metabolism everything else follows", says PHD in nutrition and founder of Lumen, Michal Mor.
According to research data obtained by 1 million metabolism measurements through the Lumen device, users are able to:
- Lose an average of 0.5 kg or 1.5 pounds of weight per week on a consistent basis
- Improve their metabolic flexibility by 66%
- Improve fasting windows to 12 hours daily
- Increase their daily movement by 1000 steps
Research also (Calcada et al , Gormsen et al ) finds that metabolic flexibility has a profound role in assessing a person's long-term health. People with good metabolic flexibility:
- Are at lower risk of developing obesity, diabetes and metabolic disorders.
- Are in a better position to gain muscle and perform better during workouts;
- Find it easier to lose weight and maintain it
Lumen is the only device in the world to measure your metabolism through the breath and track your metabolic health to prevent diseases born out of poor nutrition.
Based on the traditional RER test which was once available only in hospitals or clinics, is accessible to anyone and anywhere for the first time-revolutionizing the way we approach weight loss, fitness and healthy nutrition decision making.
Through the co2 in your breath, Lumen measures your metabolism and provides an insight into whether you're burning fats or carbs in less than a minute.
Scientific Validation
Lumen can provide numerous insights about the metabolism of an individual, as well as valuable scientific data to increase knowledge of metabolic flexibility and nutrition. In a study conducted by San Francisco State University, Lumen has been validated to meet the gold standard for metabolic measurement.
Availability
The Lumen device is available at Lumen.me , currently priced at £299.
The device comes equipped with a travel case, charging dock, USB-C Cable, and Premium Customer Support. Users can download the app for free on the Apple App Store and on Google Play.
For media: images, video and fact sheet can be found in the press kit here.
About Lumen
Lumen helps people improve their health and fitness through technology on the forefront of personalized nutrition and metabolism. Conceived and designed by twin sisters, physiology PhDs and Ironman winners, Lumen harnesses the power of our breath to measure metabolism, which is closely linked to weight, fitness and personal health. The Lumen device measures metabolism in a single breath, in less than a minute, which previously was only possible through an hour-long lab test. Available at Lumen.me , Lumen devices ship globally, with the app available on the Apple App Store and Google Play. Lumen is headquartered in Israel, with offices in the United States.
[1] Sources: The role of low-grade inflammation and metabolic flexibility in aging and nutritional modulation thereof: A systems biology approach. Available via: https://www.sciencedirect.com/science/article/pii/S0047637414000050 . Last accessed 5 May 2020.
[2] Source: Estradiol acutely inhibits whole body lipid oxidation and attenuates lipolysis in subcutaneous adipose tissue: a randomized, placebo-controlled study in postmenopausal women. Available via:https://eje.bioscientifica.com/view/journals/eje/167/4/543.xml
View source version on businesswire.com: https://www.businesswire.com/news/home/20210309005629/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Saudi Fund for Development Signs Six Development Loan Agreements Worth Over USD 403 Million with Syria5.11.2026 15:32:00 CET | Press release
The Saudi Fund for Development (SFD) has signed six concessional development loan agreements worth more than USD 403 million with the Syrian Arab Republic, marking a significant step in supporting the country’s recovery through the rehabilitation of essential infrastructure, restoration of vital public services and improvement of living conditions for communities affected by years of conflict. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105350224/en/ HRH the Crown Prince and President of the Syrian Arab Republic Al-Sharaa witness signing of agreements (Photo: AETOSWire The agreements, signed under the directives of the Custodian of the Two Holy Mosques, King Salman bin Abdulaziz Al Saud, and His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister, reflect the Kingdom’s continued commitment to supporting Syria’s development priorities. The signing ceremony was witnessed by Hi
Hyperice Unveils Normatec Elite Heat Legs: Integrated Heat Meets Dynamic Air Compression in a New Fully Wireless Design5.11.2026 15:00:00 CET | Press release
FSA/HSA-Eligible Recovery Boots Deliver Five Levels of Heat and Seven Levels of Compression, Available for Pre-Order Now Hyperice, a high-performance wellness brand, today announced the launch of Normatec Elite Heat Legs, the newest innovation in the award-winning Normatec line and the first Normatec product to incorporate heat directly into its line of dynamic air compression therapy. As the 2024 launch of Normatec Elite signified a transformative leap forward in recovery technology, Elite Heat demonstrates Hyperice’s relentless commitment to offering athletes and wellness enthusiasts alike the most comprehensive and intuitive recovery experiences in the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105782891/en/ Normatec Elite Heat demonstrates Hyperice’s relentless commitment to offering athletes and wellness enthusiasts alike the most comprehensive and intuitive recovery experiences in the world. “Innovation h
LPs Expect Private Markets Managers to Level Up in 2027: SS&C Intralinks Survey5.11.2026 15:00:00 CET | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the publication of the 2027 LP Survey. In association with Reuters Insights, SS&C Intralinks surveyed 400 professionals working in private markets, including 370 limited partners and allocators, to understand how the alternative investments market will change in the next 12 months.* “Alternatives once again delivered in 2026, and LPs are still committing capital, but their expectations of managers continue to rise,” said Ken Bisconti, general manager of SS&C Intralinks. “Technology and data capabilities now rank among the most important criteria for selecting managers, alongside investment strategy. Performance alone is no longer enough. For nearly one-third of allocators, a credible artificial intelligence (AI) strategy is now a prerequisite for allocating capital to a manager.” Key findings from the report include: Alternatives portfolios continue to outperform. 62% of respondents said their portfolios exceeded expectati
European Commission expands license for Alfasigma’s Jyseleca® (filgotinib) with approval of new indication, treatment of adults with axial spondylarthritis5.11.2026 15:00:00 CET | Press release
Jyseleca® (filgotinib) has received expanded approval for the treatment of patients with active axial spondylarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have not responded adequately to conventional therapy. EC approval follows a positive opinion from the CHMP in September 2026 and offers a new treatment option for people living with inadequately controlled axSpA in Europe. An application has been submitted to the MHRA for UK approval and is under review. In the OLINGUITO Phase 3 study, improvements in the signs and symptoms of axSpA – including spinal pain – were observed early and maintained over 52 weeks of treatment with filgotinib. This new indication builds on previous approvals for Jyseleca® for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis in Europe and the United Kingdom. The information contained within this press release is for the purpose of scientific exchange. It is intended for scientific, financia
Shonan Beauty Clinic Named to Newsweek’s “World’s Best Hospitals & Clinics for Medical Tourism 2027”5.11.2026 15:00:00 CET | Press release
Recognized in two Plastic & Reconstructive Surgery categories, liposuction and breast augmentation, among leading medical institutions across 13 countries SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced that Shonan Beauty Clinic, one of the clinic brands it supports, has been named to “World’s Best Hospitals & Clinics for Medical Tourism 2027,” an international ranking presented by Newsweek in partnership with Statista. The clinic was recognized in the Plastic & Reconstructive Surgery field, in both the liposuction and breast augmentation categories. The ranking covers six specialty fields across 13 countries. Within Plastic & Reconstructive Surgery, which comprises breast augmentation, liposuction, and rhinoplasty, each of the three categories names the top 75 institutions, and Shonan Beauty Clinic was recognized in two. T
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
